Compare Stocks

→ Biden replacement revealed? (From Paradigm Press) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADMS Adamas Pharmaceuticals	$8.22	$8.17	$4.02 ▼ $9.15	$376.37M	2.82	692,487 shs	N/A
ATXI Avenue Therapeutics	$0.13	$0.15	$0.11 ▼ $1.25	$5.96M	-0.24	4.59 million shs	290,143 shs
CTST CannTrust	C$0.64	C$0.64	C$0.38 ▼ C$8.17	C$90.27M	N/A	N/A	N/A
PHAS PhaseBio Pharmaceuticals		$0.00	$0.07 ▼ $4.08	$3.50M	2.57	848,888 shs	N/A
XERS Xeris Biopharma	$1.76 -1.1%	$2.45	$1.46 ▼ $3.26	$250.01M	2.33	1.41 million shs	1.09 million shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADMS Adamas Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
ATXI Avenue Therapeutics	-0.37%	-4.67%	-15.88%	-3.93%	-87.54%
CTST CannTrust	0.00%	0.00%	0.00%	0.00%	0.00%
PHAS PhaseBio Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	+25.00%
XERS Xeris Biopharma	-1.12%	-13.30%	-18.14%	-26.97%	-21.43%

Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS (Ad)

You might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.

Click here to find out that this 8,788% cryptocurrency is.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADMS Adamas Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ATXI Avenue Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CTST CannTrust	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PHAS PhaseBio Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
XERS Xeris Biopharma	3.4963 of 5 stars	3.5	2.0	0.0	4.2	0.0	2.5	0.6

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADMS Adamas Pharmaceuticals	N/A	N/A	N/A	N/A
ATXI Avenue Therapeutics	3.00	Buy	N/A	N/A
CTST CannTrust	N/A	N/A	N/A	N/A
PHAS PhaseBio Pharmaceuticals	N/A	N/A	N/A	N/A
XERS Xeris Biopharma	3.00	Buy	$4.88	176.99% Upside

Current Analyst Ratings

Latest ADMS, ATXI, PHAS, CTST, and XERS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
3/28/2024	XERS Xeris Biopharma	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$5.00
3/7/2024	XERS Xeris Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$5.50 ➝ $6.00

(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADMS Adamas Pharmaceuticals	$74.46M	5.05	N/A	N/A	($0.47) per share	-17.49
ATXI Avenue Therapeutics	N/A	N/A	N/A	N/A	$0.03 per share	N/A
CTST CannTrust	C$35.22M	2.56	N/A	N/A	N/A	∞
PHAS PhaseBio Pharmaceuticals	$818K	0.00	N/A	N/A	($1.93) per share	0.00
XERS Xeris Biopharma	$163.91M	1.51	N/A	N/A	($0.05) per share	-35.20

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADMS Adamas Pharmaceuticals	-$57.40M	-$1.70	N/A	N/A	N/A	-71.11%	N/A	-42.96%	N/A
ATXI Avenue Therapeutics	-$10.38M	-$1.27	N/A	∞	N/A	N/A	N/A	-335.11%	5/10/2024 (Estimated)
CTST CannTrust	-C$10.46M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
PHAS PhaseBio Pharmaceuticals	-$131.07M	-$2.13	N/A	N/A	N/A	-12,572.13%	N/A	-174.38%	N/A
XERS Xeris Biopharma	-$62.26M	-$0.45	N/A	N/A	N/A	-37.98%	-610.76%	-19.15%	5/14/2024 (Estimated)

Latest ADMS, ATXI, PHAS, CTST, and XERS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
3/18/2024	Q4 2023	ATXI Avenue Therapeutics	N/A	$0.56	+$0.56	$0.56	N/A	N/A
3/6/2024	Q4 2023	XERS Xeris Biopharma	-$0.09	-$0.10	-$0.01	-$0.10	$45.50 million	$44.39 million

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADMS Adamas Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ATXI Avenue Therapeutics	N/A	N/A	N/A	N/A	N/A
CTST CannTrust	N/A	N/A	N/A	N/A	N/A
PHAS PhaseBio Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
XERS Xeris Biopharma	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADMS Adamas Pharmaceuticals	21.25	4.53	4.17
ATXI Avenue Therapeutics	N/A	1.55	1.55
CTST CannTrust	N/A	N/A	N/A
PHAS PhaseBio Pharmaceuticals	N/A	0.47	0.47
XERS Xeris Biopharma	49.27	1.64	1.23

Ownership

Institutional Ownership

Company	Institutional Ownership
ADMS Adamas Pharmaceuticals	69.97%
ATXI Avenue Therapeutics	17.34%
CTST CannTrust	0.03%
PHAS PhaseBio Pharmaceuticals	49.02%
XERS Xeris Biopharma	42.75%

Insider Ownership

Company	Insider Ownership
ADMS Adamas Pharmaceuticals	18.90%
ATXI Avenue Therapeutics	1.80%
CTST CannTrust	N/A
PHAS PhaseBio Pharmaceuticals	9.90%
XERS Xeris Biopharma	4.36%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
ADMS Adamas Pharmaceuticals	138	45.79 million	37.13 million	Optionable
ATXI Avenue Therapeutics	3	44.26 million	43.46 million	Not Optionable
CTST CannTrust	576	141.49 million	N/A	Optionable
PHAS PhaseBio Pharmaceuticals	60	49.86 million	44.92 million	Not Optionable
XERS Xeris Biopharma	377	140.45 million	134.33 million	Optionable

ADMS, ATXI, PHAS, CTST, and XERS Headlines

Source	Headline
	Xeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) top owners are retail investors with 51% stake, while 45% is held by institutions finance.yahoo.com - April 5 at 12:23 PM
	Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) finance.yahoo.com - April 3 at 6:23 PM
	Xeris Biopharma to Participate in the 23rd Annual Needham Virtual Healthcare Conference finance.yahoo.com - April 2 at 8:50 AM
	Xeris Biopharma (NASDAQ:XERS) Now Covered by Oppenheimer marketbeat.com - March 28 at 8:29 AM
	Xeris Biopharma Surpasses 2023 Expectations with Strategic Moves Poised for 2024 Growth proactiveinvestors.com - March 18 at 9:49 PM
	Here's What Analysts Are Forecasting For Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) After Its Annual Results finance.yahoo.com - March 9 at 1:59 PM
	Xeris Biopharma (XERS) Q4 2023 Earnings Call Transcript seekingalpha.com - March 8 at 7:43 PM
	Xeris Biopharma Holdings Inc (XERS) Reports Robust Revenue Growth in Q4 and Full Year 2023 finance.yahoo.com - March 7 at 2:41 PM
	Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q4 2023 Earnings Call Transcript insidermonkey.com - March 7 at 1:01 PM
	Q4 2023 Xeris Biopharma Holdings Inc Earnings Call finance.yahoo.com - March 7 at 12:19 AM
	Xeris Biopharma Shares Drop After Weak 4Q Results marketwatch.com - March 6 at 7:18 PM
	Xeris Pharmaceuticals GAAP EPS of -$0.10 in-line, revenue of $44.39M beats by $0.84M msn.com - March 6 at 7:18 PM
	XERS Stock Earnings: Xeris Biopharma Holdings Meets EPS, Beats Revenue for Q4 2023 investorplace.com - March 6 at 2:00 PM
	Xeris Biopharma secures $200M in capital in debt refinancing deal; sees big 4Q revenue jump proactiveinvestors.com - March 6 at 9:57 AM
	Xeris Biopharma (XERS) Reports Q4 Loss, Lags Revenue Estimates zacks.com - March 6 at 9:16 AM
	Xeris Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Events businesswire.com - March 6 at 7:02 AM
	Xeris Refinances Its $150M Senior Secured Term Loan Facility With Hayfin Capital businesswire.com - March 6 at 7:00 AM
	Why Xeris (XERS) Might Surprise This Earnings Season zacks.com - March 5 at 10:46 AM
	Xeris Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on March 6, 2024 businesswire.com - February 28 at 7:00 AM
	3 Breakout Stocks Under $5 to Buy for More Upside theglobeandmail.com - February 23 at 7:13 PM
	Xeris to Present at the Oppenheimer 34th Annual Healthcare Life Science Conference finance.yahoo.com - February 5 at 9:27 AM
	Big Game or Small, Here's How to Go About Stalking a Trade realmoney.thestreet.com - February 3 at 6:45 PM
	Xeris inks licensing deal with Amgen on former Horizon drug chicagobusiness.com - January 12 at 9:32 AM
	Xeris Biopharma jumps on news of Amgen deal thepharmaletter.com - January 12 at 9:32 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

3 Value Stocks Too Small For Buffett’s Portfolio
March 28, 2024 12:16 PM
View 3 Value Stocks Too Small For Buffett’s Portfolio
Foot Locker Builds Up Another Head of Steam; Gains Imminent
March 28, 2024 10:58 AM
View Foot Locker Builds Up Another Head of Steam; Gains Imminent
5 Stocks in the Current Bull Market with Upside to Come
April 5, 2024 10:14 AM
View 5 Stocks in the Current Bull Market with Upside to Come
Can Altimmune get its GLP-1 Drug to Market Before Cash Rush Out?
April 9, 2024 6:07 AM
View Can Altimmune get its GLP-1 Drug to Market Before Cash Rush Out?
Penny Stock Quantum-Si Incorporated Readies For Lift-Off
April 9, 2024 7:14 AM
View Penny Stock Quantum-Si Incorporated Readies For Lift-Off

All Headlines

Company Descriptions

Adamas Pharmaceuticals

NASDAQ:ADMS

Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA.

Avenue Therapeutics

NASDAQ:ATXI

Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes therapies for the treatment of rare and neurologic diseases in the United States. Its lead product candidate includes AJ201, which in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous (IV) Tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. Avenue Therapeutics, Inc. was incorporated in 2015 and is based in Tampa, Florida.

CannTrust

NYSE:CTST

CannTrust Holdings Inc. produces and sells medical and recreational cannabis in Canada. It sells dried cannabis and cannabis extracts to the medical patients. CannTrust Holdings Inc. was incorporated in 2015 and is headquartered in Vaughan, Canada.

PhaseBio Pharmaceuticals

NASDAQ:PHAS

PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapies for cardiovascular diseases. The firm's pipeline includes: bentracimab (PB2452), a novel reversal agent for the antiplatelet therapy ticagrelor, pemziviptadil (PB1046), a once-weekly vasoactive intestinal peptide receptor agonist for the treatment of pulmonary arterial hypertension, and PB6440, an oral agent for the treatment of resistant hypertension. The company was founded by Ashutosh Chilkoti and Clay Bernardin Thorp in January 2002 and is headquartered in Malvern, PA.

Xeris Biopharma

NASDAQ:XERS

Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial